CN116354599A - Boron-containing bioactive glass and preparation method and application thereof - Google Patents
Boron-containing bioactive glass and preparation method and application thereof Download PDFInfo
- Publication number
- CN116354599A CN116354599A CN202310406166.2A CN202310406166A CN116354599A CN 116354599 A CN116354599 A CN 116354599A CN 202310406166 A CN202310406166 A CN 202310406166A CN 116354599 A CN116354599 A CN 116354599A
- Authority
- CN
- China
- Prior art keywords
- parts
- boron
- bioactive glass
- containing bioactive
- source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/062—Glass compositions containing silica with less than 40% silica by weight
- C03C3/064—Glass compositions containing silica with less than 40% silica by weight containing boron
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Geochemistry & Mineralogy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses boron-containing bioactive glass, a preparation method and application thereof, wherein the boron-containing bioactive glass comprises the following components in parts by mole: b (B) 2 O 3 20-30 parts of SiO 2 20-30 parts of CaO, 20-30 parts of MgO, 6-8 parts of SrO 6-8 parts of Na 2 O2-3 parts, K 2 O2-5 parts and P 2 O 5 2-4, the invention provides the boron-containing bioactive glass, and the large area of the boron-containing bioactive glass on diabetic feet, bedsores, burns, various skin surface ulcers and the like is realized through the synthesis of raw materialsAnd (3) treating the wound surface.
Description
Technical Field
The invention relates to the technical field of biological materials, in particular to boron-containing bioactive glass and a preparation method and application thereof.
Background
Over 670 ten thousand patients worldwide suffer from chronic wounds, the treatment of the chronic wounds is always a difficult problem of clinical wound care, the disease course is long, serious dysfunction is often caused, and great pain and inconvenience are caused to the patients. Wound care biomaterials have evolved from traditional cotton gauze dressings, minerals and ointments, etc. to advanced skin substitutes now containing hydrogels, sponges, foams, fibers, sprays, even cells and growth factors, but they still fail to restore the intact structure and physiology of the native host skin in the injured area, or lack skin accessory regeneration, leaving a gap from ideal wound care materials. How to find a reasonable treatment scheme to promote the rapid repair of chronic wounds becomes a problem to be solved in clinical work.
The bioactive glass is an inorganic synthetic material, the shelf life can be up to 3 years, and the bioactive glass has almost no obvious toxicity and side effect to human body, and is widely used for orthopedic surgery and bone defect at present
Dental care (Prevest Micron->
) However, although bioactive glass can be transplanted to autologous skin in the clinical treatment of wound surface, the bioactive glass has better curative effect on large wound surface, and can not be used because of pathological state of autologous skin against pathological wound surface such as diabetes. However, other therapeutic means such as heterogeneous skin repair, and repair of chronic large wounds such as diabetes by synthetic or natural constituent materials still have certain limitations, such as immune rejection, easy infection, poor repair effect, troublesome operation, and high price.
Therefore, the provision of a material which is beneficial to the effective repair and reconstruction of acute/chronic large wounds is urgent.
Disclosure of Invention
The present invention aims to solve at least one of the technical problems in the prior art described above. Therefore, the invention provides the boron-containing bioactive glass, and the treatment of large-area wound surfaces such as diabetic feet, bedsores, burns, various skin surface ulcers and the like by the boron-containing bioactive glass is realized through the synthesis of raw materials.
According to an embodiment of the first aspect of the present invention, there is provided a boron-containing bioactive glass comprising, in parts by mole: b (B) 2 O 3 20-30 parts of SiO 2 20-30 parts of CaO, 20-30 parts of MgO, 6-8 parts of SrO 6-8 parts of Na 2 O2-3 parts, K 2 O2-5 parts and P 2 O 5 2-4。
According to an embodiment of the first aspect of the invention, at least the following advantages are achieved:
1. the boron-containing bioactive glass has excellent biocompatibility and strong adjustability and has healing promoting effect, the bioactive microenvironment formed by material degradation can obviously accelerate the healing of wound surface wounds through the proportion adjustment of elements, and the migration of keratinocytes in epithelial tissues, and the healing promoting material taking the boron-containing bioactive glass as the raw material can obviously promote the healing speed of full-layer skin defects (20 mm) on the back of SD rats, accelerate skin contraction and promote skin re-epithelialization; under the condition of healing of full-layer skin large defects (20 mm) of the wound surface of a diabetic rat, the wound surface keratinocyte migration can be effectively promoted, and the wound surface healing is accelerated.
2. One of the key reasons for difficult healing of chronic wounds based on diabetes is that the wounds are in a continuous inflammatory process, pathological wounds mainly comprise inflammatory M1 type macrophages, and boron-containing bioactive glass generates an ionic microenvironment in a degradation process, wherein borate ([ BO) 3 ]3-) can accelerate macrophage to change into anti-inflammatory M2 phenotype by regulating polarization of macrophage, and improve anti-inflammatory activity of wound tissue, silicate (SiO) 4 4- ) Calcium ion (Ca) 2+ ) Magnesium ions (Mg) 2+ ) Strontium ion (Sr) 2 + ) Can induce and promote blood vessel formation, and zinc ion (Zn) 2+ ) And copper ion (Cu) 2+ ) Has antibacterial effect, and can reduce wound infection, and [ BO ] 3 ]3-、Ca 2+ These can be added by upregulating the cell migration related genes K-10, K-14 and InvolurinRapid re-epithelialization, thereby promoting healing at different stages of wound healing and shortening healing time.
3. The boron-containing bioactive glass has good biological safety, no obvious cytotoxicity and good blood compatibility.
According to some embodiments of the invention, the boron-containing bioactive glass comprises the following components in parts by mole: b (B) 2 O 3 26-28 parts of SiO 2 26-28 parts of CaO, 22-24 parts of MgO, 7-8 parts of SrO 6-7 parts of Na 2 O2-3 parts, K 2 O4-5 parts and P 2 O 5 2-3 parts.
The boron-containing bioactive glass has the advantages of small boron ratio, low cost and simple operation, and can greatly reduce the treatment cost of the acute and chronic wounds.
According to some embodiments of the invention, the raw materials for preparing the boron-containing bioactive glass further comprise ZnO.
According to some embodiments of the invention, the raw material for preparing the boron-containing bioactive glass further comprises CuO.
Zinc ion (Zn) 2+ ) Copper ion (Cu) 2+ ) Can induce and promote the formation of blood vessels, promote the healing at different stages of wound healing, and shorten the healing time.
According to some embodiments of the invention, the boron-containing bioactive glass comprises the following components in parts by mole: b (B) 2 O 3 20-30 parts of SiO 2 20-30 parts of CaO, 20-30 parts of MgO, 6-8 parts of SrO 6-8 parts of ZnO 0.01-1 part of CuO0.01-1 part of Na 2 O2-3 parts, K 2 O2-5 parts and P 2 O 5 2-4 parts.
According to some embodiments of the invention, the size of the boron-containing bioactive glass is 20-60 μm.
According to an embodiment of the second aspect of the present invention, there is provided a method for preparing the boron-containing bioactive glass, comprising the steps of: b source, si source, ca source, mg source, sr source Na source and K source and P source compounds are mixed.
According to some embodiments of the invention, the preparation method of the boron-containing bioactive glass comprises the following steps: b source, si source, ca source, mg source, sr source, zn source, cu source, P source, na source and K source compounds are mixed.
According to some embodiments of the invention, the temperature of the mixing is 1000 ℃ to 1500 ℃.
According to some embodiments of the invention, the mixing comprises heating, cooling.
According to some embodiments of the invention, the cooling includes quenching on a cold steel plate.
According to some embodiments of the invention, the Si source comprises SiO 2 。
According to some embodiments of the invention, the B source comprises H 3 BO 3 And Na (Na) 2 B 4 O 7 At least one of them.
According to some embodiments of the invention, the Ca source includes CaO, ca (OH) 2 、CaCl 2 、Ca(HCO 3 ) 2 And CaCO (CaCO) 3 At least one of them.
According to some embodiments of the invention, the Mg source comprises MgO, mg (OH) 2 、(MgCO 3 ) 4 ·Mg(OH) 2 ·5H 2 O and MgCl 2 At least one of them.
According to some embodiments of the invention, the Sr source comprises SrO, srCO 3 And SrCl 2 At least one of them.
According to some embodiments of the invention, the P source comprises P 2 O 5 、H 3 PO 4 、Na 3 PO 4 、Na 2 HPO 4 And NaH 2 PO 4 ·2H 2 At least one of O.
According to some embodiments of the invention, the Na source comprises Na 2 O、NaOH、NaHCO 3 、Na 2 CO 3 、Na 2 HPO 4 、NaH 2 PO 4 、Na 3 PO 4 And at least one of NaCl.
According to some embodiments of the invention, the K source comprises K 2 O、KOH、KHCO 3 、K 2 CO 3 、K 2 HPO 4 、KH 2 PO 4 、K 3 PO 4 And at least one of KCl.
According to some embodiments of the invention, the Zn source comprises ZnO, znCO 3 、[ZnCO 3 ] 2 ·[Zn(OH) 2 ] 3 And ZnCl 2 At least one of them.
According to some embodiments of the invention, the Cu source comprises CuO, cuCO 3 ·Cu(OH) 2 And ZnCl 2 At least one of them.
According to an embodiment of the third aspect of the present invention, a wound healing material is provided, and the raw materials for preparing the wound healing material include the boron-containing bioactive glass.
According to some embodiments of the invention, the raw materials for preparing the wound healing material further comprise at least one of antibiotics, growth factors, analgesics and conventional radiotherapy and chemotherapy drugs.
According to some embodiments of the invention, the dosage form of the wound healing material comprises at least one of a gel material, an ointment, and an oil gauze.
According to some embodiments of the invention, the gel material further comprises vaseline and paraffin.
According to some embodiments of the invention, the gel material further comprises liquid paraffin, vitamin E, humectant and antioxidant.
According to some embodiments of the invention, the petrolatum comprises white petrolatum.
According to some embodiments of the invention, the paraffin comprises liquid paraffin.
The gel material has good injectability under the conditions of the components, can be suitable for coating and covering various irregular wounds, can prevent the adhesion problem of tissues, gauze and other dressings caused by bandaging, and can effectively block the adhesion of bacteria and tissues.
According to some embodiments of the present invention, the gel material is prepared from raw materials including, by weight, 0.1-10 parts of boron-containing bioactive glass, 50-95 parts of vaseline, 0-10 parts of paraffin, 0-5 parts of vitamin E, 0-5 parts of humectant, and 0-0.2 parts of antioxidant.
According to some embodiments of the invention, the method of preparing the gel material comprises mixing the preparation raw materials of the gel material.
According to some embodiments of the invention, the gel material is prepared by mixing at a temperature of 30-60 ℃.
According to some embodiments of the invention, in the method of preparing the gel material, the method of mixing comprises stirring.
The preparation method of the gel material has at least the following beneficial effects: the raw materials of the invention are simply mixed at low temperature and stirred to obtain the homogeneous boron-containing bioactive glass gel, and the raw materials of the process are cheap and easy to obtain and can be produced in large scale.
According to an embodiment of the fourth aspect of the present invention, there is provided the use of a boron-containing bioactive glass in wound healing.
According to some embodiments of the invention, the wound comprises a chronic wound and an acute wound.
According to some embodiments of the invention, the chronic wound comprises a diabetic foot wound.
Drawings
The invention is further described with reference to the accompanying drawings and examples, in which:
FIG. 1 is an external view of a boron-containing bioactive glass gel material of the present invention;
FIG. 2 shows the wound healing of the boron-containing bioactive glass gel material of the present invention;
FIG. 3 is a chart showing the staining of wound healing tissue sections of the boron-containing bioactive glass gel material of the present invention;
FIG. 4 is a chart showing the promotion of keratinocyte migration of the boron-containing bioactive glass gel material of the present invention;
FIG. 5 is a schematic illustration of the bacteriostatic behavior of the boron-containing bioactive glass frit of the present invention;
FIG. 6 is a graph showing cytotoxicity of the boron-containing bioactive glass gel material of the present invention;
FIG. 7 shows the haemolysis rate of the boron-containing bioactive glass gel material of the present invention.
Detailed Description
The conception and the technical effects produced by the present invention will be clearly and completely described in conjunction with the embodiments below to fully understand the objects, features and effects of the present invention. It is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments, and that other embodiments obtained by those skilled in the art without inventive effort are within the scope of the present invention based on the embodiments of the present invention.
Example 1
The gel material of the boron-containing bioactive glass is prepared by the specific preparation method:
s1: weighing a certain amount of H 3 BO 3 、SiO 2 、CaCO 3 、(MgCO 3 ) 4 ·Mg(OH) 2 ·5H 2 O、SrCO 3 、[ZnCO 3 ] 2 ·[Zn(OH) 2 ] 3 、CuCO 3 ·Cu(OH) 2 、NaH 2 PO 4 ·2H 2 O, anhydrous Na 2 CO 3 And anhydrous K 2 CO 3 Mixing uniformly by ternary mixer, melting the mixture at 1300 ℃, and quenching molten glass water on a cooled steel plate to obtain a product with a mole fraction of B 2 O 3 20 parts of SiO 2 34 parts of CaO, 16 parts of MgO, 10 parts of SrO 5 parts, 1 part of ZnO and Na 2 O5 and K 2 O5 part, P 2 O 5 5 parts of boron-containing bioactive glass I, wherein the particle size of the boron-containing bioactive glass is 20-60 mu m.
S2: heating and melting vaseline at 60 ℃, and then, according to the mass ratio, the vaseline: adding the boron-containing bioactive glass in the ratio of 9:1, fully stirring and mixing, turning off a heating power supply, and continuously stirring until the temperature is reduced to room temperature. The material was named as boron-containing bioactive glass gel I, and the appearance diagram is shown in FIG. 1.
Example 2
The gel material of the boron-containing bioactive glass is prepared by the specific preparation method:
s1: weighing a certain amount of H 3 BO 3 、SiO 2 、CaCO 3 、(MgCO 3 ) 4 ·Mg(OH) 2 ·5H 2 O、SrCO 3 、[ZnCO 3 ] 2 ·[Zn(OH) 2 ] 3 、CuCO 3 ·Cu(OH) 2 、NaH 2 PO 4 ·2H 2 O, anhydrous Na 2 CO 3 And anhydrous K 2 CO 3 Mixing uniformly by ternary mixer, melting the mixture at 1300 ℃, and quenching molten glass water on a cooled steel plate to obtain a product with a mole fraction of B 2 O 3 27 parts of SiO 2 27 parts of CaO 23 parts, mgO 8 parts, srO 6 parts and Na 2 O3 and K 2 O4 part, P 2 O 5 2 parts of boron-containing bioactive glass II, the particle size of which is 20-60 mu m.
S2: heating and melting vaseline at 50 ℃, and then proportioning the vaseline according to the mass ratio: adding the boron-containing bioactive glass at a ratio of 50:1, fully stirring and mixing, turning off a heating power supply, and continuously stirring until the temperature is reduced to room temperature. The material was designated as boron-containing bioactive glass gel II.
Example 3
The gel material of the boron-containing bioactive glass is prepared by the specific preparation method:
s1: weighing a certain amount of H 3 BO 3 、SiO 2 、CaCO 3 、(MgCO 3 ) 4 ·Mg(OH) 2 ·5H 2 O、SrCO 3 、[ZnCO 3 ] 2 ·[Zn(OH) 2 ] 3 、CuCO 3 ·Cu(OH) 2 、NaH 2 PO 4 ·2H 2 O, anhydrous Na 2 CO 3 And anhydrous K 2 CO 3 Mixing uniformly by ternary mixer, melting the mixture at 1300 ℃, and quenching molten glass water on a cooled steel plate to obtain a product with a mole fraction of B 2 O 3 27 parts of SiO 2 27 parts of CaO, 22 parts of MgO, 8 parts of,SrO 6 part, cuO 1 part and Na 2 O3 and K 2 O4 part, P 2 O 5 2 parts of boron-containing bioactive glass III, the particle size of which is 20-60 mu m.
S2: heating and melting vaseline at 40 ℃, and then proportioning the vaseline according to the mass ratio: adding the boron-containing bioactive glass in a ratio of 99:1, fully stirring and mixing, turning off a heating power supply, and continuously stirring until the temperature is reduced to room temperature. The material was designated as boron-containing bioactive glass gel III.
Comparative example 1
This comparative example a commercial silicate bioactive glass gel product (bioactive glass gel) was prepared, and this comparative example differs from example 2 in that boron was not included, with the remaining conditions being the same.
Comparative example 2
Comparative example A gel material of bioactive glass was prepared, the difference between this comparative example and example 2 being the mole fraction of B 2 O 3 37 parts of SiO 2 17 parts of CaO 23 parts, mgO 8 parts, srO 6 parts and Na 2 O3 and K 2 O4 part, P 2 O 5 2 parts of boron-containing bioactive glass, and the rest conditions are the same.
Test example 1
The test example tests the influence of different materials on promoting the healing condition of normal wound surface.
SD rats weigh about 200-300g, and the male and female animals are not limited to 6 animals in each group. SD rats fasted for 12h prior to the experiment. SD rats were gas anesthetized with isoflurane and the anesthetized SD rats were incubated. The back of the SD rat is subjected to dehairing treatment, then the SD rat is disinfected by iodophor, a circular operation area with the diameter of 20mm is determined by a circular polytetrafluoroethylene ring (with the inner diameter of 20 mm), a 20mm full-layer skin defect model is manufactured by operation, and the circular polytetrafluoroethylene ring is sewed on the skin, so that the influence of the skin autogenous shrinkage of the SD rat on wound healing is reduced. A wound was made on each side of the back of each SD rat. Physiological saline is applied to a negative blank control group, the experimental group is the boron-containing bioactive glass gel prepared in the examples 1-3, and the positive control group is the bioactive glass gel of the comparative example 1The method comprises the steps of carrying out a first treatment on the surface of the After applying the material to the wound, tegaderm is applied separately TM Film (3M) seals the wound surface and then fixes the wound with an elastic bandage. Changing the medicine every 3-4 days, and observing the wound healing condition. As shown in fig. 2, animal experiments prove that compared with the control group, the boron-containing bioactive glass gel I, II and III have good wound surface repairing capability, and can remarkably improve the wound surface healing speed.
Test example 2
The test example tests the influence of different materials on the promotion of the healing condition of the diabetic wound surface.
SD rats weighing about 300-400g, 6 in each group. SD rats fasted for 12h prior to the experiment. Streptozotocin was injected intraperitoneally at a dose of 55mg/kg based on the weight of SD rats, which showed hyperglycemia after 10 days>16.7 mmol/L), weight loss, polydipsia, polyphagia and diuresis, and successfully constructs a type I diabetes rat model. After 45 days of rearing diabetic SD rats successfully modeled, skin wound healing experiments were performed. Diabetic SD rats were gas anesthetized with isoflurane. In the back dehairing treatment of diabetic SD rats, iodophor disinfection, 2 full-layer skin defect models with the inner diameter of 20mm are created on the two sides of the back by using a circular mold. Physiological saline is applied to a negative blank control group, the experimental group is the boron-containing bioactive glass gel prepared in the examples 1-3, and the positive control group is the bioactive glass gel without bioactive glass gel and the bioactive glass gel of the comparative example 1; after applying the material to the wound, tegaderm is applied separately TM Film (3M) seals the wound surface and then fixes the wound with an elastic bandage. Changing the medicine every 3-4 days, and observing the wound healing condition. HE staining of wound site tissue was performed on days 3, 7, 14 and 21, respectively. The HE staining results of fig. 3 show that the boron-containing bioactive glass prepared in example 2 not only significantly promoted wound contraction (fig. 2), but also significantly promoted epithelialization on day 3 (fig. 3), and that a continuous thickness of re-epithelialized tissue was seen at day 3 at the wound lesion of example 2, whereas no wound was formed in the other control and experimental groups; furthermore, at 21 days, example 2 had skin accessory organ neo-tissue formation at the wound (fig. 3). In addition, compared with comparative example 2 having a high boron content, the green body of example 2Better biocompatibility (figure 6) and can promote the healing of chronic wounds of diabetes more quickly.
Test example 3
The present test example tests the effect of different materials on the promotion of keratinocyte migration.
The samples were mixed with serum-free medium and subjected to shaking table leaching at 37℃for 24h according to the leaching standard of 0.2 g/mL. And then filtering the leaching solution in an ultra-clean bench by using a sterile filter membrane to a sterile centrifuge tube to prepare a sterile sample leaching solution. Recovering east human immortalized epidermal cells (HaCaT cells), and carrying out subsequent experiments after 2-3 passages and cell viability recovery. A marker pen and a ruler are used behind the 6-hole plate, and two straight lines perpendicular to each other are uniformly drawn through the center of a circle; 5X 10 of the additive is added to each hole 5 And culturing the cells for 24 hours, and scribing by using a sterile gun head and perpendicular to the cell plane along the scratch designed by a marker pen before after the cells are paved and adhered to the whole bottom surface. And adding a proper amount of sterile PBS into each hole, cleaning for 2-3 times, lightly vibrating the hole plate, washing off cells scratched when the hole plate is not adhered to the wall and scratched, observing the scratches clearly under a microscope, and recording by using a fluorescent microscope for bright field photographing, wherein no cell residue exists in the middle of the scratches. According to the experimental setup, the well plates and samples were grouped and sample extracts (serum free) were added to the well plates for incubation. Placing the cells into 5% CO at 37deg.C 2 The incubator was incubated for 24 hours, the plates were removed, and scratches were observed in the bright field using a fluorescence microscope, and compared with scratches of the control group before 24 hours. Fig. 4 shows that the boron-containing bioactive glass gel group (I, II and III) significantly promotes keratinocyte migration, especially the boron-containing bioactive glass II group, compared to the blank group, the no bioactive glass gel group, and the bioactive glass gel group (comparative example 1). Further verifies the curative effect of promoting the rapid formation of wound surface epidermis by the in vivo boron-containing bioactive glass gel, thereby promoting wound healing.
Test example 4
The test example tests the influence of different materials on the bacteriostasis of staphylococcus aureus in vitro.
The material was plated out to the bottom of a 6-well plate, and then 2mL of LB medium (1×106 CFU) containing staphylococcus aureus was added to each well (n=5). After incubation for 24h in an incubator at 37℃the plate was vibrated by rotation at 100rpm, 100. Mu.L of medium was aspirated and the absorbance of the suspension at 600nm was measured. The inhibition rate of the material to staphylococcus aureus is= (A1-A0)/A0 multiplied by 100 percent. A0 is absorbance of the blank control group, and A1 is absorbance of the experimental group. Fig. 5 shows that the boron-containing bioactive glass gel groups (I and III) all have a significant bacteriostatic effect against staphylococcus aureus compared to the blank, the no bioactive glass gel group and the bioactive glass gel group (comparative example 1).
Test example 5
The test example tests the effect of in vitro cytotoxicity of different materials.
According to the in vitro cytotoxicity test of national standard GB/T16886.5-2017, the test example tests the cytotoxicity condition of different boron-containing bioactive glass gel materials on L929 fibroblasts. The biocompatibility of the boron-containing bioactive glass gel leach with L929 fibroblasts was assessed using the CCK-8 kit. L929 cells were cultured in medium (DMEM/FBS, 9:1) at 37℃with 5% CO 2 Is cultured. 100 mu L L929 cell suspension (5X 10) 3 cells/cm -2 ) Added to 96-well plates and incubated for 24h. The medium was removed and 100. Mu.L of material extract (0.2 g/mL) was added to a 96-well plate. The well plate was then placed in 5% CO at 37℃ 2 Is cultured for 24 hours. CCK-8 reagent was added as indicated. Absorbance of the sample was recorded at 450nm using a microplate reader and cell viability was calculated using the formula [ | (A-A) 0 )|/A 0 ×100％]A is the absorbance of the sample, A 0 Absorbance was measured for the medium blank. FIG. 6 shows that the prepared boron-containing bioactive glass gel material meets the requirements of in-vitro cytotoxicity test of national standard GB/T16886.5-2017, and has good cell compatibility.
Test example 6
The test example tests the effect of the in vitro hemolytic properties of different materials.
The test example tests the influence of different boron-containing bioactive glass gel materials on the erythrocyte hemolysis rate. Collecting arterial blood of the edge of a healthy New Zealand white rabbit ear, and placing the arterial blood in a blood collection tube containing an anticoagulant sodium citrate. Fresh anticoagulated rabbit blood (8 mL) was taken and diluted by adding physiological saline (10 mL). 3 test tubes of each test sample group, 5g of test sample and 10mL of physiological saline are added into each test tube; 3 test tubes of a negative control group, wherein 10mL of physiological saline is added into each test tube; positive control tube set 3 test tubes, each with 10mL distilled water. After all test tubes were incubated in a constant temperature water bath (37 ℃ C.+ -1 ℃ C.) for 30min, 0.2mL of the diluted rabbit blood was added to each test tube, gently shaken, and incubated in a constant temperature water bath (37 ℃ C.+ -1 ℃ C.) for 60min. The liquid in the pouring tube was placed in a 15mL centrifuge tube and centrifuged at 800g for 15min. The supernatant was transferred into a cuvette and absorbance was measured at 545nm according to spectrophotometry (chinese pharmacopoeia four-part rule 0401). The absorbance of the test sample combined control group is an average value of 3 branch pipes, the absorbance of the negative control group is not more than 0.03, and the absorbance of the positive control group is 0.8+/-0.03, otherwise, the test is repeated. The calculation is performed as follows:
hemolysis ratio= (test article absorbance-negative control group absorbance)/(positive control group absorbance-negative control group absorbance) ×100%. A hemolysis ratio of less than 5% is judged to be excellent in blood compatibility. Figure 7 shows that the prepared boron-containing bioactive glass gel material has hemolysis rate less than 5% and excellent blood compatibility.
The embodiments of the present invention have been described in detail with reference to the accompanying drawings, but the present invention is not limited to the above embodiments, and various changes can be made within the knowledge of one of ordinary skill in the art without departing from the spirit of the present invention. Furthermore, embodiments of the invention and features of the embodiments may be combined with each other without conflict.
Claims (10)
1. The boron-containing bioactive glass is characterized by comprising the following components in parts by mole: b (B) 2 O 3 20-30 parts of SiO 2 20-30 parts of CaO, 20-30 parts of MgO, 6-8 parts of SrO 6-8 parts of Na 2 O2-3 parts, K 2 O2-5 parts and P 2 O 5 2-4。
2. The boron-containing bioactive glass of claim 1,the boron-containing bioactive glass is characterized by comprising the following components in parts by weight: b (B) 2 O 3 26-28 parts of SiO 2 26-28 parts of CaO, 22-24 parts of MgO, 7-8 parts of SrO 6-7 parts of Na 2 O2-3 parts, K 2 O4-5 parts and P 2 O 5 2-3 parts.
3. The boron-containing bioactive glass of claim 1, wherein the raw materials for preparing the boron-containing bioactive glass further comprise ZnO; preferably, the raw materials for preparing the boron-containing bioactive glass further comprise CuO.
4. The boron-containing bioactive glass of claim 1, wherein the boron-containing bioactive glass has a size of 20-60 μιη.
5. A method for preparing the boron-containing bioactive glass of claim 1, comprising the steps of: the B source, si source, ca source, mg source, sr source, na source, K source, and P source compounds were mixed.
6. A wound healing material, characterized in that the raw materials for preparing the wound healing material comprise the boron-containing bioactive glass as claimed in any one of claims 1 to 4.
7. The wound healing material of claim 6, wherein the dosage form of the wound healing material comprises at least one of a gel material, an ointment material, and an oil gauze material.
8. The wound healing material according to claim 7, wherein the gel material is prepared from raw materials further comprising vaseline and paraffin.
9. Use of a boron-containing bioactive glass as claimed in any one of claims 1 to 4 in wound healing.
10. The use according to claim 9, wherein the wound comprises chronic and acute wounds; preferably, the chronic wound surface comprises a diabetic foot wound surface.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310406166.2A CN116354599A (en) | 2023-04-06 | 2023-04-06 | Boron-containing bioactive glass and preparation method and application thereof |
| PCT/CN2023/121103 WO2024207695A1 (en) | 2023-04-06 | 2023-09-25 | Boron-containing bioactive glass, and preparation method therefor and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310406166.2A CN116354599A (en) | 2023-04-06 | 2023-04-06 | Boron-containing bioactive glass and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116354599A true CN116354599A (en) | 2023-06-30 |
Family
ID=86908282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310406166.2A Pending CN116354599A (en) | 2023-04-06 | 2023-04-06 | Boron-containing bioactive glass and preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN116354599A (en) |
| WO (1) | WO2024207695A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024207695A1 (en) * | 2023-04-06 | 2024-10-10 | 深圳先进技术研究院 | Boron-containing bioactive glass, and preparation method therefor and use thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101259277A (en) * | 2008-04-25 | 2008-09-10 | 同济大学 | Novel orthopaedics medicaments carrier system and preparation thereof |
| CN102657893A (en) * | 2012-05-07 | 2012-09-12 | 浙江大学 | Medical nano-fiber sponge material and preparation method and application thereof |
| CN107510704A (en) * | 2017-10-18 | 2017-12-26 | 张家港蓝智生物科技有限公司 | A kind of antiallergy burn and scald paste containing bio-vitric |
| CN107617121A (en) * | 2017-10-13 | 2018-01-23 | 广州润虹医药科技股份有限公司 | A kind of skin wound biology induced activity dressing and its preparation method and application |
| CN109437559A (en) * | 2018-11-19 | 2019-03-08 | 湖北中创医疗用品有限公司 | Bioactivity glass, bioactivity glass gel and its preparation method and application |
| CN113171224A (en) * | 2021-04-08 | 2021-07-27 | 浙江大学 | Implanted bandage for promoting bone injury repair and preparation method thereof |
| CN113599574A (en) * | 2021-07-28 | 2021-11-05 | 苏州大学 | Regeneration material for muscle repair and preparation method thereof |
| CN113698560A (en) * | 2021-09-13 | 2021-11-26 | 深圳先进技术研究院 | Antibacterial and anti-inflammatory composite hydrogel precursor solution and preparation method and application thereof |
| CN114524612A (en) * | 2022-02-10 | 2022-05-24 | 深圳市中科海世御生物科技有限公司 | Amorphous silicon-based material and preparation method and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103848574A (en) * | 2012-12-06 | 2014-06-11 | 上海诺帮生物科技有限公司 | Preparation of strontium-containing bioglass powder and preparation method of strontium-containing porous bioglass bracket |
| US20150283300A1 (en) * | 2014-04-03 | 2015-10-08 | Gregory J. Pomrink | Bioactive glasses with surface immobilized peptides and uses thereof |
| US10751367B2 (en) * | 2016-05-27 | 2020-08-25 | Corning Incorporated | Bioactive glass microspheres |
| CN109020230A (en) * | 2018-09-28 | 2018-12-18 | 吉林省米阳光医疗器械科技有限公司 | A kind of magnesium, strontium-reinforced bioactive glass ceramic |
| CN116354599A (en) * | 2023-04-06 | 2023-06-30 | 深圳先进技术研究院 | Boron-containing bioactive glass and preparation method and application thereof |
-
2023
- 2023-04-06 CN CN202310406166.2A patent/CN116354599A/en active Pending
- 2023-09-25 WO PCT/CN2023/121103 patent/WO2024207695A1/en unknown
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101259277A (en) * | 2008-04-25 | 2008-09-10 | 同济大学 | Novel orthopaedics medicaments carrier system and preparation thereof |
| CN102657893A (en) * | 2012-05-07 | 2012-09-12 | 浙江大学 | Medical nano-fiber sponge material and preparation method and application thereof |
| CN107617121A (en) * | 2017-10-13 | 2018-01-23 | 广州润虹医药科技股份有限公司 | A kind of skin wound biology induced activity dressing and its preparation method and application |
| CN107510704A (en) * | 2017-10-18 | 2017-12-26 | 张家港蓝智生物科技有限公司 | A kind of antiallergy burn and scald paste containing bio-vitric |
| CN109437559A (en) * | 2018-11-19 | 2019-03-08 | 湖北中创医疗用品有限公司 | Bioactivity glass, bioactivity glass gel and its preparation method and application |
| CN113171224A (en) * | 2021-04-08 | 2021-07-27 | 浙江大学 | Implanted bandage for promoting bone injury repair and preparation method thereof |
| CN113599574A (en) * | 2021-07-28 | 2021-11-05 | 苏州大学 | Regeneration material for muscle repair and preparation method thereof |
| CN113698560A (en) * | 2021-09-13 | 2021-11-26 | 深圳先进技术研究院 | Antibacterial and anti-inflammatory composite hydrogel precursor solution and preparation method and application thereof |
| CN114524612A (en) * | 2022-02-10 | 2022-05-24 | 深圳市中科海世御生物科技有限公司 | Amorphous silicon-based material and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| JINGXIN DING 等: "Regulated contribution of local and systemic immunity to new bone regeneration by modulating B/Sr concentration of bioactive borosilicate glass", 《MATERIALS TODAY BIO》, pages 1 - 15 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024207695A1 (en) * | 2023-04-06 | 2024-10-10 | 深圳先进技术研究院 | Boron-containing bioactive glass, and preparation method therefor and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024207695A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kargozar et al. | Can bioactive glasses be useful to accelerate the healing of epithelial tissues? | |
| Yang et al. | Sustained release of magnesium and zinc ions synergistically accelerates wound healing | |
| WO2019091150A1 (en) | Alginate wound repair dressing and preparation method thereof | |
| CN102657893A (en) | Medical nano-fiber sponge material and preparation method and application thereof | |
| CN101301487A (en) | Gelatine/biological activity glass composite sponge dressing and preparation thereof | |
| CN116354599A (en) | Boron-containing bioactive glass and preparation method and application thereof | |
| CN113511811A (en) | Multifunctional mesoporous biomaterial, preparation method and application | |
| Yang et al. | Copper ion/gallic acid MOFs-laden adhesive pomelo peel sponge effectively treats biofilm-infected skin wounds and improves healing quality | |
| RU2706726C1 (en) | Wound coating | |
| Chang et al. | A bioartificial dermal regeneration template promotes skin cell proliferation in vitro and enhances large skin wound healing in vivo | |
| Qu et al. | Evaluation of anti-bacterial and wound healing activity of the fruits of Amorpha fruticosa L. | |
| CN112121223B (en) | Sericin medical dressing and production method thereof | |
| Lee et al. | Vessel-derived decellularized extracellular matrices (VdECM): novel bio-engineered materials for the wound healing | |
| Fan et al. | SB216763-loaded multifunctional copper-doped bioglass 3D printed scaffold promotes wound healing and functional skin regeneration | |
| CN108653800A (en) | Containing bioactivity glass and/or arginic wound repair dressing and the preparation method and application thereof | |
| CN108042841A (en) | A kind of biological dressing and preparation method thereof and purposes | |
| Miguez-Pacheco et al. | Bioactive glasses for soft tissue engineering applications | |
| CN114344331B (en) | Application of small molecule compound in preparation of medicine for activating primordial follicle | |
| CN109793757B (en) | Composition for inhibiting growth of skin scar and preparation method and application thereof | |
| Klama-Baryła et al. | Experience in using fetal membranes: the present and new perspectives | |
| CN108434507A (en) | Ion mediation dressing and its preparation method and application | |
| CN107149701A (en) | Carry type i collagen/calcium hydroxy apetite Bionics Bone of carbapenem antibiotic | |
| CN103893811B (en) | The application of a kind of preparation method of bio-vitric felt and products thereof | |
| CN104826167A (en) | Injectable autologous bone repair material and preparation method thereof | |
| CN117462650B (en) | Application of polypeptide A in promoting bone regeneration or bone repair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |